EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

25th April 2014
EMA/CHMP/189248/2014
Procedure Management and Business Support Division

Committee for Medicinal Products for Human Use (CHMP)

Final Minutes of meeting held on 17-20 March 2014

Chair: Tomas Salmonson – Vice-chair: Pierre Demolis

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. The procedures discussed by the CHMP are on-going and therefore certain aspects of them are considered confidential. Additional details on some of these procedures is published in the CHMP meeting highlights once the procedures are finalised and start of referrals are also available. For orphan medicinal products and products that received an opinion at this meeting, the applicant details are published as this information is already publicly available. The same applies for the product name for products that received an opinion at this meeting. Documents mentioned in these minutes cannot be released at present as they are currently in draft format or are classified as confidential. They will become public when adopted in their final form or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Of note, this set of minutes is a working document primarily designed for CHMP members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8416
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

AGENDA (4) and Annex to CHMP agenda of the CHMP plenary session to be held on 17-20 March 2014	The agenda and annex were adopted with amendments.
TIMESCHEDULE (version 4) of the CHMP plenary session to be held on 17-20 March 2014	The timeschedule was adopted.
MINUTES () of the CHMP plenary session held on 17-20 February 2014 and ORGAM meeting held on 10 March 2014.	The Minutes of the CHMP plenary session held 17-20 February 2014 were adopted.
MINUTES (EMA/CHMP/143039/2014) of the CHMP ORGAM meeting held on 10 March 2014	The Minutes of the March 2014 CHMP ORGAM meeting held on 10 March 2014 were adopted together with all decisions taken at that meeting.
MEMBERSHIP ANNOUNCEMENT	The Committee welcomed Dimitrios Kouvelas new CHMP member from Greece, Panayiotis Triantafyllis new Cypriot member and Georgios Savva new alternate from Cyprus. The Committee also noted that this was the last meeting for Bengt Ljungberg alternate member from Sweden and thanked him for all his contributions to the work undertaken by the Committee.
LIST of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held on 17-20 March 2014	The pre-meeting list was noted. See also 21 List of participant
CONFLICT OF INTERESTS	In accordance with the Agency's revised policy and procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests). Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting (see end of document). All decisions taken at this meeting were made in presence of a quorum of members – i.e. 22 or more members were present in the room.
Draft Agenda of CHMP meeting to be held on 22-25 April 2014 CHMP meeting: **for information**	The draft agenda was noted.

Table of Contents

1 ORAL EXPLANATIONS

1.1 Pre-authorisation Procedure Oral Explanations

(EMEA/H/C/002085), (tilmanocept), (used in the delineation and localisation of lymph nodes)
List of Outstanding Issues adopted in December 2013, October 2013.
List of Questions adopted in May 2013.
An Oral explanation was held on Wednesday 19 March 2014 at 9.00.
After the oral explanation the CHMP agreed to seek further clarification in writing from the applicant as well as to consult the SAG Oncology.
See section 2.2 List of Outstanding Issues

(EMEA/H/C/002643), (trametinib), (treatment of unresectable or metastatic melanoma with a BRAF V600 mutation)
List of Outstanding Issues adopted in November 2013.
List of Questions adopted in June 2013.
An Oral explanation was held on Tuesday 18 March at 14.30.

1.2 Re-examination Procedure Oral Explanation

Masican (EMEA/H/C/002670), Orphan (MASITINIB), Applicant: AB Science, (treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST))
Negative Opinion adopted in November 2013.
An Oral explanation was held on Tuesday 18 March at 17.00.
See also 6 Re-examination procedures (New Applications) under Article 9(2) of Regulation No 726/2004

1.3 Post-authorisation Procedure Oral explanation

No items

1.4 Referral Procedures Oral Explanations

No items

2 NEW APPLICATIONS

2.1 Opinions – New full applications

ANORO (EMEA/H/C/002751), (umeclidinium bromide/vilanterol), Applicant: Glaxo Group Ltd., (treatment of chronic obstructive pulmonary disease (COPD))
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted in November 2013, September 2013.
List of Questions adopted in May 2013.
Opinion in February 2013.
The final Assessment Report was adopted via written procedure on 17.03.2014.

Ebilfumin (EMEA/H/C/003717), (oseltamivir), Applicant: Actavis Group PTC ehf, Generic of Tamiflu,
1) Treatment of influenza in patients one year of age and older who present with symptoms typical of influenza, when influenza virus is circulating in the community.
2) Treatment of infants less than 1 year of age during a pandemic influenza outbreak.
3) Post-exposure prevention in individuals 1 year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.
4) Post-exposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak)
Generic application (Article 10(1) of Directive No 2001/83/EC)
List of Outstanding Issues adopted in December 2013 and February 2014.
List of Questions adopted in September 2013.
The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus, together with the CHMP Assessment report and Translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

Entyvio (EMEA/H/C/002782), (vedolizumab), Applicant: Takeda Pharma A/S, (treatment of Ulcerative Colitis and Crohn's Disease)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted in December 2013.
List of Questions adopted in July 2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by majority (28 positive out of 30 votes), together with the CHMP Assessment report and Translation timetable.
Furthermore, the CHMP considered that vedolizumab is a new active substance, as claimed by the applicant.
The divergent positions (Daniela Melchiorri, Pierre Demolis) were appended to the opinion.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

Folcepri (EMEA/H/C/002570), Orphan, (etarfolatide), Applicant: Endocyte Europe, B.V., (indicated for single photon emission computed tomography (SPECT) imaging)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted in January 2014, November 2013.
List of Questions adopted in March 2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus, together with the CHMP Assessment report and Translation timetable.
Furthermore, the CHMP considered that etarfolatide is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

Neocepri (EMEA/H/C/002773), Orphan, (folic acid), Applicant: Endocyte Europe, B.V., (indicated for the enhancement of Folcepri single photon emission computed tomography (SPECT) image quality.)
Known active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted in January 2014, November 2013.
List of Questions adopted in March 2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus, together with the CHMP Assessment report and Translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

Vynfinit (EMEA/H/C/002571), Orphan, (vintafolide), Applicant: Endocyte Europe, B.V., (treatment of platinum resistant ovarian cancer (PROC))
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted in January 2014, November 2013.
List of Questions adopted in March 2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus, together with the CHMP Assessment report and Translation timetable.
Furthermore, the CHMP considered that vintafolide is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The Committee noted the Letter of Recommendations dated 25 February 2014.
The summary of opinion was circulated for information.

Jardiance (EMEA/H/C/002677), (empagliflozin), Applicant: Boehringer Ingelheim International GmbH, (treatment of type II diabetes mellitus)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted in December 2013.
List of Questions adopted in July 2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus, together with the CHMP Assessment report and Translation timetable.
Furthermore, the CHMP considered that empagliflozin is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

OLYSIO (EMEA/H/C/002777), (simeprevir), Applicant: Janssen-Cilag International N.V., (indication in combination with other medicinal products for the treatment of chronic hepatitis C in adult patients)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted in January 2014.
List of Questions adopted in September 2013.
The Committee discussed some late pending changes in the SmPC. The Committee was reminded that if information was not provided in the SmPC, then it could not be mentioned in the EPAR. The Committee agreed to set up a drafting group in the margin of the meeting to sort the matter.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus, together with the CHMP Assessment report and Translation timetable.
Furthermore, the CHMP considered that simeprevir is a new active substance, as claimed by the

applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

REVINTY ELLIPTA (EMEA/H/C/002745), (fluticasone furoate / vilanterol trifenatate), Applicant: Glaxo Group Ltd, (treatment of asthma)
Informed consent application (Article 10c of Directive No 2001/83/EC)
The Committee was reminded that the original application had been adopted by majority therefore voting was needed to conclude the review of this duplicate application.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by majority, (19 positive out of 29 votes), together with the CHMP Assessment report and Translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The divergent positions (Pieter de Graeff, Pierre Demolis, Kristina Dunder, Harald Enzmann, Hubert Leufkens, Daniela Melchiorri, Ivana Mikacic, Jan Mueller-Berghaus, Concepcion Prieto Yerro, Bruno Sepodes) were appended to the opinion.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

SYLVANT (EMEA/H/C/003708), Orphan, (siltuximab), Applicant: Janssen-Cilag International NV, (treatment of multicentric Castleman's disease (MCD))
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Questions adopted in January 2014.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus, together with the CHMP Assessment report and Translation timetable. This application was evaluated under accelerated assessment.
Furthermore, the CHMP considered that siltuximab is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.
The Committee noted the letter of recommendations dated 20 March 2014.
The Committee adopted the BWP report.

2.2 Day 180 List of outstanding issues – New full applications

(EMEA/H/C/002835), (insulin glargine), (treatment of diabetes mellitus)
List of Outstanding Issues adopted in March 2014. List of Questions adopted in October 2013.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.
In addition the CHMP agreed to consult the relevant Working Parties/Advisory Groups, including the BMWP, SmPC Advisory Group and HCPWP on whether there would be reasons to revise the standard statement on biosimilars (section 5.1 of the SmPC) as recommended by the SmPC Guideline.

(EMEA/H/C/002647), (insulin degludec / liraglutide), (treatment of type 2 diabetes mellitus)
List of Outstanding Issues adopted in March 2014.
List of Questions adopted in October 2013.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.
The CHMP agreed to the request by the applicant for an extension to the clock stop.
The Committee adopted the BWP report.

(EMEA/H/C/002314), (bazedoxifene / estrogens conjugated), (treatment of oestrogen deficiency and osteoporosis)
List of Outstanding Issues adopted in March 2014. List of Questions adopted in November 2012.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.
The CHMP agreed to the request by the applicant for an extension to the clock stop.
The Committee adopted a List of Questions to the PKWP.

(EMEA/H/C/002655), (tacrolimus), (indicated for the prophylaxis of transplant rejection in adult kidney allograft recipients.)
List of Outstanding Issues adopted in March 2014. List of Questions adopted in September 2013.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/002085), (tilmanocept), (used in the delineation and localisation of lymph nodes)
List of Outstanding Issues adopted in December 2013, October 2013.
List of Questions adopted in May 2013. See also section I Oral Explanations
The Committee was reminded of the outstanding issues in this application.
An Oral explanation was held on Wednesday 19 March 2014 at 9.00. The Committee agreed to consult the SAG Oncology.
The Committee adopted a 3rd List of Outstanding Issues.
The CHMP agreed to an additional extension to the clock stop to respond to the 3rd List of Outstanding Issues with a specific timetable.
The List of Questions to the SAG Oncology was adopted via written procedure after the Plenary.

(EMEA/H/C/002813), (simoctocog alfa), (treatment and prophylaxis of bleeding (congenital factor VIII deficiency))
List of Outstanding Issues adopted in March 2014. List of Questions adopted in October 2013.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.
The Committee adopted the BWP report.

(EMEA/H/C/002827), (peginterferon beta-1a), (treatment of relapsing multiple sclerosis)
List of Outstanding Issues adopted in March 2014. List of Questions adopted in October 2013.
The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a List of Outstanding Issues with a specific timetable.
The Committee adopted the BWP report.

(EMEA/H/C/002780), (ospemifene), (treatment of vulvar and vaginal atrophy (VVA))
List of Outstanding Issues adopted in March 2014. List of Questions adopted in July 2013.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues.
The CHMP agreed to the request by the applicant for an extension to the clock stop together with a specific timetable.

(EMEA/H/C/002633), Orphan, (tobramycin), Applicant: PARI Pharma GmbH, (treatment of chronic pulmonary infection)
List of Outstanding Issues adopted in October 2013.
List of Questions adopted in February 2013.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a 2nd List of Outstanding Issues with a specific timetable.

(EMEA/H/C/002347), (perflubutane), (ultrasound imaging agent indicated for the detection of coronary artery disease (CAD))
List of Outstanding Issues adopted in November 2013.
List of Questions adopted in February 2013.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.

2.3 Day 120 List of Questions – New full applications

(EMEA/H/C/003969), (aclidinium / formoterol fumarate dihydrate), (maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD))
See also (EMEA/H/C/003745).
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

(EMEA/H/C/002830), Orphan, (mifepristone), Applicant: FGK Representative Service GmbH, (treatment of signs and symptoms of endogenous Cushing's syndrome in adults)
List of Questions adopted in March 2014.
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

(EMEA/H/C/003729), (secukinumab), (treatment of plaque psoriasis)
List of Questions adopted in March 2014.
The Committee discussed the issues identified in this application
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.
The Committee adopted the BWP report.

(EMEA/H/C/003745), (aclidinium / formoterol fumarate dihydrate), (maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD))
List of Questions adopted in March 2014. See also (EMEA/H/C/003969)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

(EMEA/H/C/003720), (faldaprevir), (treatment of chronic genotype-1 hepatitis C virus (HCV) infection)
List of Questions adopted in March 2014.
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

(EMEA/H/C/003843), (idelalisib), (treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) and refractory indolent non-Hodgkin lymphoma (iNHL))
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.
Furthermore the CHMP agreed to consult the SWP and the list of questions to this working party will be adopted via written procedure.

(EMEA/H/C/003791), Orphan, (ibrutinib), Applicant: Janssen-Cilag International NV, (treatment of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma)
List of Questions adopted in March 2014.
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

(EMEA/H/C/002807), (human fibrinogen / human thrombin), (fibrocaps (human plasma-derived fibrinogen and thrombin) is used as an adjunct to haemostasis)
List of Questions adopted in March 2014.
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of

Questions.
The Committee adopted the BWP report.

(EMEA/H/C/003771), (nonacog gamma), (treatment of haemophilia B)
List of Questions adopted in March 2014.
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.
The Committee adopted the BWP report.

(EMEA/H/C/002754), (dolutegravir / abacavir / lamivudine), (treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-naïve or are infected with HIV without documented or clinically suspected resistance to any of the three antiretroviral agents listed above)
List of Questions adopted in March 2014.
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

2.4 Update on on-going new applications for Centralised Procedures

(EMEA/H/C/002548), Orphan, (afamelanotide), Applicant: Clinuvel (UK) Limited, (treatment of phototoxicity in adult patients with erythropoietic protoporphyria (EPP))
List of Outstanding Issues adopted in March 2013.
List of Questions adopted in July 2012.
The CHMP adopted the List of Questions to an Ad-hoc expert group and noted the draft list of members for this group.
Call for further nominations for the ad hoc expert group meeting.

(EMEA/H/C/002661), Orphan Applicant: medac Gesellschaft fuer klinische Spezialpraeparate mbH, (recombinant l-asparaginase), (combination therapy for B/T cell lymphoblastic leukaemia (ALL) or B/T cell lymphoblastic lymphoma (LBL))
The adoption of the CHMP similarity assessment report was postponed to April CHMP.

2.5 Products in the Decision Making Phase

Vokanamet (EMEA/H/C/002656), (canagliflozin /metformin), Applicant: Janssen-Cilag International N.V., (treatment of type 2 diabetes mellitus)
New active substance at the time of submission of the application (Article 8(3) of Directive No 2001/83/EC)
Opinion in February 2014.
List of Outstanding Issues adopted in December 2013.
List of Questions adopted in July 2013.
The Committee adopted a revised Opinion by consensus to amend the statement on the new active

substance status together with a revised Assessment Report.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

3 EXTENSION OF MARKETING AUTHORISATION ACCORDING TO ANNEX I OF REG. 1234/2008

3.1 Extension of marketing authorisation according to Annex I of Reg. 1234/2008; Opinions

Imatinib Actavis (EMEA/H/C/002594/X/0003), (imatinib), MAH: Actavis Group PTC ehf, Generic of Glivec, Rapporteur: Reynir Arngrímsson, PRAC Rapporteur: Dolores Montero Corominas, "Line extension to add a new strength, 400mg hard capsule for the extended set of indications already authorised for the reference product Glivec."
List of Outstanding Issues adopted in February 2014. List of Questions adopted in November 2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive Opinion by consensus, together with the CHMP Assessment report and Translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

3.2 Extension of marketing authorisation according to Annex I of Reg. 1234/2008; Day 180 List of outstanding issues

Ventavis (EMEA/H/C/000474/X/0043), (iloprost), MAH: Bayer Pharma AG, Rapporteur: Pierre Demolis, PRAC Rapporteur: Evelyne Falip, "To add a new strength:

20 microgram/ml nebuliser solution (in 30 and 168 ampoules package sizes)"
List of Outstanding Issues adopted in March 2014.
List of Questions adopted in November 2013.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues Questions with specific timetable.
The CHMP adopted the Assessment Report on similarity

3.3 Extension of marketing authorisation according to Annex I of Reg. 1234/2008; Day 120 List of Questions

Signifor (EMEA/H/C/002052/X/0010), Orphan, (pasireotide), MAH: Novartis Europharm Ltd, Rapporteur: Kristina Dunder, Co-Rapporteur: Joseph Emmerich, PRAC Rapporteur: Qun-Ying Yue, "Line extension application for Signifor to add 20mg, 40mg and 60mg powder and solvent for suspension for injection in the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative, or who are inadequately controlled on treatment with other somatostatin analogues."
List of Questions adopted in March 2014.
The Committee discussed the issues identified in this application which related to a questionable relative benefit/risk compared to other alternative treatments for this population.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

3.4 Update on on-going Extension application according to Annex I of Reg. 1234/2008

No items

4 TYPE II VARIATIONS - Extension of indication procedures

4.1 Opinions or Requests for Supplementary information - Type II variation; Extension of indication

Busilvex (EMEA/H/C/000472/II/0019), (busulfan), MAH: Pierre Fabre Médicament, Rapporteur: Arantxa Sancho-Lopez, "Extension of indication for fludarabine followed by Busilvex (FB) as conditioning treatment prior to hematopoietic progenitor cell transplantation (HPCT) in adult patients when such combinations are considered the best available option. Conseuqnetly, changes are proposed to sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC and the package leaflet. The MAH also took the opportunity to update the products information in line with QRD template version 9.0."
Request for Supplementary Information adopted in March 2014, October 2013.
The Committee was reminded of the status of this application and its identified issues which related to several aspects of the clinical efficacy.
The Committee adopted a 2nd Request for Supplementary Information with a specific timetable.

ECALTA (EMEA/H/C/000788/II/0026), (anidulafungin), MAH: Pfizer Limited, Rapporteur: Pieter de Graeff, Co-Rapporteur: Jens Ersbøll, PRAC Rapporteur: Sabine Straus, "Following the CHMP assessment of efficacy and safety data of Ecalta in neutropenic patients with invasive candidiasis and non-neutropenic patients with Cancida deep tissue infection (MEA 014.3), update of sections 4.1, 4.4, 4.8 and 5.1 of the SmPC . The Package Leaflet is updated accordingly.
In addition the MAH proposes to take the opportunity of this variation to bring the SmPC in line with the QRD Annex I template version 9."
The Committee discussed the issues identified in this application which related mainly to possible lack of efficacy in neutropenic patients.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Halaven (EMEA/H/C/002084/II/0011), (eribulin), MAH: Eisai Europe Ltd., Rapporteur: Bengt Ljungberg, Co-Rapporteur: Jens Ersbøll, "This application concerns an extension of the indication of Halaven 0.44 mg/ml solution for injection to earlier lines of metastatic breast cancer following the outcome of a Phase 3 study, Study 301. Changes have been made to SmPC sections 4.1, 4.8, and 5.1. The Package leaflet has been updated accordingly. Furthermore the product information has been updated in line with the latest version of QRD template (version 9)."
Request for Supplementary Information adopted in March 2014, December 2013, July 2013.
The Committee discussed the issues identified in this application which related to several aspects of the clinical efficacy and the wording of the indication. The members discussed the clinical data and agreed by majority that the data was considered sufficient to confirm non-inferiority in the extended indication. Regarding the proposed indication some concern was raised on the proposed exclusion of her2 patients. It was agreed to seek the view of the MAH on this aspect.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Humira (EMEA/H/C/000481/II/0127), (adalimumab), MAH: AbbVie Ltd., Rapporteur: Kristina Dunder, Co-Rapporteur: Daniela Melchiorri, "Extension of indication in Enthesitis-related arthritis (ERA) in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Consequently, the MAH proposed the update of sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC. The Package Leaflet was proposed to be updated in accordance."

The Committee was reminded of the status of this application and its identified issues which related mainly to the benefit/risk balance for the treatment of children with ERA. In addition, further justification of the proposed indication should also take into account the possibility of extrapolating pharmacokinetics, efficacy and safety data from already approved indications to the currently proposed target population.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Pandemrix (EMEA/H/C/000832/II/0069), (pandemic influenza vaccine (h1n1) (split virion, inactivated, adjuvanted) a/california/7/2009 (h1n1)v like strain (x-179a)), MAH: GlaxoSmithKline Biologicals, Rapporteur: Greg Markey, PRAC Rapporteur: Julie Williams, "Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC to reflect data currently available on H1N1 influenza disease burden, effectiveness and safety of Pandemrix and epidemiology of narcolepsy. The Package Leaflet is updated accordingly. The MAH took also the opportunity to update the list of post-authorisation measures in Annex II."
Request for Supplementary Information adopted in March 2014.
The Committee was reminded of the status of this application and its identified issues, which related to the benefit risk assessment in the currently authorised indication.
The Committee adopted a Request for Supplementary Information with a specific timetable. The Committee did not agree to an extension to the clock stop to respond to the Request for Supplementary Information.

Pegasys (EMEA/H/C/000395/II/0073), (peginterferon alfa-2a), MAH: Roche Registration Ltd, Rapporteur: Kristina Dunder, Co-Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Qun-Ying Yue, "Extension of Indication for Pegasys to include the use of other products used for the treatment of Hepatitis C. The package leaflet is updated accordingly."
Request for Supplementary Information adopted in February 2014.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive Opinion by consensus together with the CHMP Assessment Report and translation timetable. The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendation. The summary of opinion was circulated for information.

Stelara (EMEA/H/C/000958/II/0036), (ustekinumab), MAH: Janssen-Cilag International N.V., Rapporteur: Ian Hudson, Co-Rapporteur: David Lyons, "Update to section 5.1 of the SmPC with data showing that ustekinumab reduces the rate of progression of peripheral joint damage. The package leaflet has been updated accordingly. Section 4.8 of the SmPC has been updated with data from the phase 3 studies of ustekinumab in psoriatic arthritis (PsA)."
Request for Supplementary Information adopted in November 2013.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive Opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendation.
The summary of opinion was circulated for information.

Tasigna (EMEA/H/C/000798/II/0061), Orphan, (nilotinib), MAH: Novartis Europharm Ltd, Rapporteur: Jens Ersbøll, Co-Rapporteur: Harald Enzmann, PRAC Rapporteur: Doris Stenver, "Extension of indication of Tasigna 200mg hard capsules for the treatment of adult patients with Philadelphia chromosome positive CML in the chronic phase who have not achieved a molecular response greater than or equal to a 4.5-log reduction with imatinib treatment". Consequently the MAH proposes changes to sections 4.1, 4.2, 4.8 and 5.1 of the SmPC."
Request for Supplementary Information adopted in October 2013.
The Committee was reminded of the status of this application and its identified issues, which related to several clinical efficacy aspects.
The Committee adopted a 2nd Request for Supplementary Information with a specific timetable.

Tresiba (EMEA/H/C/002498/II/0006), (insulin degludec), MAH: Novo Nordisk A/S, Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue, "Update of sections 4.2 and 5.1 of the SmPC in order to include guidance for prescribers on the use of Tresiba in combination with GLP-1 receptor agonists. The Package Leaflet was proposed to be updated accordingly.
Furthermore, the MAH proposed this opportunity to bring the PI in line with the latest QRD template version 9 and to include some editorial changes.
This variation application contains an updated RMP.
The requested variation proposed amendments to the SmPC, Annex II, Labelling and Package Leaflet."
Request for Supplementary Information adopted in January 2014.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive Opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendation.
The summary of opinion was circulated for information.

Victoza (EMEA/H/C/001026/II/0023), (liraglutide), MAH: Novo Nordisk A/S, Rapporteur: Pieter de Graeff, "Update of the SmPC sections 4.1, 4.2, 4.4, 4.7, 4.8 and 5.1 in order include information on the use of liraglutide in combination with basal insulin.
The PL is proposed to be updated accordingly."
Request for Supplementary Information adopted in January 2014.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive Opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendation.
The summary of opinion was circulated for information.

4.2 Update on on-going Type II variation - Extension of indications

No items

5 ANCILLARY MEDICINAL SUBSTANCES IN MEDICAL DEVICES

5.1 Opinions/ List of outstanding issues / List of Questions

(EMEA/H/D/003740)

(Plasma Proteins with at least 96% human albumin),

The Committee agreed to the request from the Applicant dated 14 March 2014 for an extension of clock stop for the submission of responses to Day 120 List of Questions

6 RE-EXAMINATION PROCEDURE (NEW APPLICATIONS) UNDER ARTICLE 9(2) OF REGULATION No 726/2004

Masican (EMEA/H/C/002670) (MASITINIB), Applicant: AB Science, Rapporteur: Jens Ersbøll, Co-Rapporteur: Greg Markey, (treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST)) Negative Opinion adopted in November 2013. See also 1 Oral Explanations

The members noted the report from the SAG Oncology held on 5 March 2014.

An Oral explanation was held on Tuesday 18 March at 17.00.

The Committee adopted a negative Opinion recommending the refusal of granting of the conditional marketing authorisation by consensus together with the CHMP Assessment Report. The grounds for refusal were amended.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The refusal question-and-answer document was circulated for information.

Serelaxin (EMEA/H/C/002817), Applicant: Novartis Europharm Ltd, (serelaxin), Re-examination (treatment of acute heart failure)

The CHMP agreed to consult the SAG Cardiovascular.

The CHMP noted the revised provisional date for submission of the detailed grounds for re-examination

Call for nominations for SAG CVS meeting

7 RE-EXAMINATION PROCEDURE (TYPE II VARIATIONS) UNDER ARTICLE 6(9) OF COMMISSION REGULATION EC NO 1085/2003

No items

8 WITHDRAWAL OF APPLICATION

DITELOS (EMEA/H/C/002593) (Colecalciferol, Strontium Ranelate), Les Laboratoires Servier, (treatment of osteoporosis)

The Committee noted the letter from the applicant dated 17 March 2014 informing of the decision to withdraw the MAA.

ISSARLOS (EMEA/H/C/002756) (Colecalciferol, Strontium Ranelate), Les Laboratoires Servier, (treatment of osteoporosis)

See Ditelos (EMEA/H/C/002593)

9 PROCEDURE UNDER ARTICLE 83(1) OF REGULATION (EC) 726/2004 (COMPASSIONATE USE)

Sofosbuvir (compassionate use) (EMEA/H/K/003891/CU)
Gilead Sciences International Ltd, (hepatitis C virus infection in pre and post liver transplant patients)
The CHMP adopted the amendment to the Assessment Report.

10 PRE-SUBMISSION ISSUES

No items

11 POST-AUTHORISATION ISSUES

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.

alli (EMEA/H/C/000854) (orlistat), MAH: Glaxo Group Ltd, Rapporteur: Rafe Suvarna, Co-Rapporteur: Dimitrios Kouvelas, (treatment of overweight and obesity)

Avonex (EMEA/H/C/000102) (Interferon Beta-1a), MAH: Biogen Idec, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Johann Lodewijk Hillege,
The CHMP considered the outcomes of a meta-analysis of publicly available RCT data on medicines used in the treatment of multiple sclerosis (Cochrane coll. review published in 2013), particularly with respect to Avonex. The CHMP noted that the conclusions of the review were mainly based on relative comparisons of Avonex with other medicinal products for multiple sclerosis. While acknowledging that medicines authorised later might be considered relatively more efficacious, the CHMP was of the view that with the overall current knowledge of the product´s efficacy and safety, the benefit-risk balance of Avonex is still considered positive.

Ad-hoc Influenza Working Group:
The Committee noted the report from the Ad Hoc Influenza working group to the BWP.
The Committee adopted the report as well as the EU Recommendation for the Seasonal Influenza Vaccine Composition for the Season 2014/2015.

Kalydeco (EMEA/H/C/002494/II/0013), Orphan, (ivacaftor), MAH: Vertex Pharmaceuticals (U.K.) Ltd., Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Miguel-Angel Macia, "Update of sections 4.8 and 5.1 of the SmPC to reflect the interim analysis at week 96 of study VX08-770-105, an open-label extension of studies VX08-770-102 and 103."
Request for Supplementary Information adopted in January 2014.
The Committee discussed the issues identified in this application which related mainly to some clinical aspects.
The Committee adopted a Request for Supplementary information together with a specific timetable.

Relvar Ellipta (EMEA/H/C/002673) (fluticasone furoate/vilanterol), MAH: Glaxo Group Ltd, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: David Lyons, PRAC Rapporteur: Miguel-Angel

Macia, PRAC Co-Rapporteur: Almath Spooner, (treatment of asthma and COPD)

Pradaxa (EMEA/H/C/000829/ LEG 042) (Dabigatran Etexilate Mesilate), MAH: Boehringer Ingelheim International GmbH, Rapporteur: Jens Heisterberg, Co-Rapporteur: Pierre Demolis, (prevention of venous thromboembolic events)
The CHMP adopted a list of questions to the MAH regarding the analysis of the RELY trial.

Afinitor (EMEA/H/C/001038/R/0036), (everolimus), MAH: Novartis Europharm Ltd, Rapporteur: Harald Enzmann, Co-Rapporteur: Bengt Ljungberg, PRAC Rapporteur: Martin Huber,
List of Outstanding Issues adopted in January 2014.
The CHMP noted the PRAC advice recommending one additional five-year renewal based primarily on the on-going post-authorization study BOLERO-6 (CRAD001Y2201), which is expected to yield important new efficacy and safety data relevant for benefit/risk of the currently approved indication of advanced HR+ breast cancer, and on the limited use in the recently approved new indication advanced HR+ breast cancer.
The CHMP adopted by consensus that an additional 5-year renewal should be requested.

Avastin (EMEA/H/C/000582) (BEVACIZUMAB), Applicant: Roche Registration Ltd, Rapporteur: Jens Ersbøll, Co-Rapporteur: Ingunn Hagen Westgaard,
Follow up from February 2014.
Fire III study compared bevacizumab plus FOLFIRI to cetuximab plus FOLFIRI as a frontline treatment for patients with KRAS wild-type metastatic colorectal cancer (mCRC)
The CHMP adopted the response from the Oncology Working Party including a List of Questions to the MAH.

12 REFERRAL PROCEDURES

12.1 Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

No items

12.2 Requests for CHMP Opinion under Article 5(3) and 57 (1)p of Regulation (EC) No 726/2004

Propylene glycol in IV formulations for children under 4 years of age (EMEA/H/A-5(3)/1317)
Rapporteur: Bruno Sepodes, Co-Rapporteurs: Milena Stain, Hubert Leufkens,
Review of the safety of the excipient propylene glycol in IV formulations for short term use in children
The CHMP adopted an opinion by consensus, concluding that based on the limited overall quality, non-clinical and clinical data currently available, no recommendation on a safe dose for propylene glycol in formulations for paediatric patients under 4 years of age can be made.
Furthermore the CHMP concluded that well-designed clinical trials investigating the safety of propylene glycol exposure and reflective of common clinical use in terms of duration and quantity are needed to allow a better understanding of propylene glycol safety in children.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

12.3 Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

No items

12.4 Disagreement between Member States on application for medicinal product (Potential serious risk to Public Health) –under Article 29(4) of Directive 2001/83/EC

Dexamed 5 mg Tablets (EMEA/H/A-29/1375) Dexamfetamine Sulphate film coated tablets), Kohne Pharma GmbH, Rapporteur: Greg Markey, Co-Rapporteur: Johann Lodewijk Hillege, Article 29(4) procedure triggered by the Netherlands on the following grounds: enhanced risk for dependence and abuse potential of this product compared to other treatment options in ADHD and lack of convincing evidence for the efficacy in a second line setting – film coated tablets.
The CHMP adopted a List of Outstanding Issues together with a List of Questions to experts and response timetable by written procedure before the March plenary meeting.
Responses to list of outstanding issues: 12.02.2014; start of the procedure: 18.02.2014; Assessment report: 05.03.2014; Comments from CHMP: 10.03.2014; 2nd List of Outstanding Issues and list of questions to experts (adoption by written procedure): 14.03.2014; Oral explanation and CHMP Opinion: May 2014 CHMP
Call for nominations of experts for SAG Psychiatry meeting

12.5 Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

Sandostatin LAR (EMEA/H/A-30/1355) (Octreotide acetate) Novartis Pharma AG group of companies and associated companies Rapporteur: Agnes Gyurasics, Co-Rapporteur: Robert James Hemmings,
List of Outstanding Issues adopted in November 2014. List of Questions adopted in May 2013.
The Committee was reminded of the status of this referral and its remaining outstanding issues concerning different sections of the SmPC.
The CHMP adopted a 2nd List of Outstanding Issues with a specific timetable.
Adoption of List of outstanding issues 2: 20.03.2014, Responses to List of outstanding issues 2: 02.05.2014, Restart of procedure: 27.05.2014, Joint assessment report: 11.06.2014, Comments from CHMP: 16.06.2014, List of outstanding issues / Oral explanation / CHMP Opinion: June 2014 CHMP

Sandostatin (EMA/H/A-30/1354) (Octreotide acetate) Novartis Pharma AG Group of companies and associated companies Rapporteur: Agnes Gyurasics, Co-Rapporteur: Robert James Hemmings,
List of Outstanding Issues adopted in November 2014. List of Questions adopted in May 2013.
The Committee was reminded of the status of this referral and its remaining outstanding issues concerning different sections of the SmPC.
The CHMP adopted a 2nd List of Outstanding Issues with a specific timetable.
Adoption of List of outstanding issues 2: 20.03.2014, Responses to List of outstanding issues 2: 02.05.2014, Restart of procedure: 27.05.2014, Joint assessment report: 11.06.2014, Comments from CHMP: 16.06.2014, List of outstanding issues / Oral explanation / CHMP Opinion: June 2014 CHMP

Seroquel IR&XR (EMA/H/A-30/1362) (quetiapine), Astra Zeneca, Rapporteur: Hans Hillege, Co-Rapporteur: Melinda Sobor, Helena Matos
List of Questions adopted in June 2013. List of Outstanding Issues adopted in November 2013.

The CHMP adopted a 2nd List of Outstanding Issues with a specific timetable due to comments raised on the use of Seroquel during pregnancy.
2nd List of Outstanding issues: 20.03.2014; Responses to 2nd list of outstanding issues: 08.04.2014**;** Restart of the procedure: 22.04.2014; Assessment report: 07.05.2014; Comments from CHMP: 13.05.2014; List of outstanding issues or CHMP opinion: May 2014 CHMP

12.6 Community Interests - Referral under Article 31 of Directive 2001/83/EC

Gadolinium containing contrast agents, Gd-Cas (EMEA/H/A-31/1097)
Rapporteur: Rafe Suvarna, Co-Rapporteur: Pieter de Graeff,
FUM related to the 3rd annual cumulative safety reviews on nephrogenic systemic fibrosis (NSF)
The CHMP adopted the assessment report on the second monthly update and interim analysis submission requested by CHMP in November 2013.

12.7 Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

Estradiol (topical use) (EMEA/H/A-31/1336)
Re-examination Rapporteur: Arantxa Sancho-Lopez, Re-examination Co-Rapporteur: Milena Stain,
Review of the benefit-risk balance of medicinal products containing estradiol for intravaginal administration and administration on the skin of the vulva due to observed high systemic absorption which may lead to safety issues
The CHMP noted the grounds for re-examination and the timetable.
Re-examination – receipt of letter of intent from MAH on: 03.01.2014
Re-examination – receipt of detailed grounds from MAH on: 06.03.2014
Re-examination – Start of re-examination procedure: 07.03.2014
Re-examination – Rapporteur assessment report and Co-Rapporteur assessment report circulated to CHMP: 08.04.2014
Re-examination – CHMP comments: 14.04.2014
Re-examination – Updated Rapporteur assessment report and updated Co-Rapporteur assessment report circulated to CHMP: 17.04.2014
Re-examination – Oral explanation/CHMP final opinion: April 2014 CHMP meeting
The CHMP agreed that no SAG was required at this time.

12.8 Procedure under Article 107(2) of Directive 2001/83/EC

Ketoprofen formulation for topical use (EMEA/H/A-107/1259)
(Ketum), Rapporteur: Joseph Emmerich, Co-Rapporteur: Radka Montoniová,
The CHMP adopted the Assessment report of 3-years cumulative analysis of photosensitivity reactions including photo allergy reactions together with a report of the effectiveness of risks minimisation measures (submissions received on 14 November 2013 as well as, for the patch formulation, submissions received on 13 November 2013, 29 November 2013, 24th February 2014 and 6 March 2014).
The CHMP also adopted the Assessment reports of the Surveillance study of photocontact dermatitis leading to hospitalization in Europe with a special focus on topical ketoprofen and other topical NSAIDs, including evaluation of severe photosensitivity reactions (PASS pilot study) (submissions received on 14 November 2013).
The CHMP considered and discussed the data submitted by the MAHs with regard to the two above-mentioned conditions to the Marketing Authorisations for all ketoprofen topical formulations, including the patch formulation.
The CHMP adopted a List of Questions to the MAHs with a specific timetable.
Start: 21.03.2014; Submissions from MAHs: 02.05.2014; Assessment Report: 11.06.2014; Comments from CHMP: 16.06.2014; CHMP conclusions: June 2014 CHMP

12.9 Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003)

No items

12.10 Procedure under Article 29 Regulation (EC) 1901/2006

No items

12.11 Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

No items

13 PHARMACOVIGILANCE ISSUES

Summary of recommendations and advice of PRAC meeting held on 4-7 March 2014: **For information**	The Committee noted the report. The members noted the Summary of recommendations and advices of the PRAC meeting.
List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for March 2014: **For adoption**	The EURD list was adopted.
Early Notification System: March 2014 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety	See individual items

Concerns) Accompanied by Communication to the General Public: **for information**	

14 INSPECTIONS

14.1 GMP Inspections

Request for GMP Inspections: **For adoption**	*Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections.*

14.2 GCP Inspections

Request for GCP Inspections: **For adoption**	*Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections.*

14.3 Pharmacovigilance Inspections

Pharmacovigilance Inspection Report: **For information**	*Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections.*

14.4 GLP Inspections

Request for GLP Inspections: **For adoption**	*Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections.*

15 INNOVATION TASK FORCE

15.1 Minutes of ITF: For information

15.2 Briefing meetings (Innovation Task Force)

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information.

15.3 Eligibility to EMA scientific services

No items

15.4 Requests for CHMP Opinion under Article 57 (1)P of Regulation (EC) NO 726/2004

Update on CHMP opinion under Art. 57 (1)P of Regulation (EC) No 726/2004

The CHMP adopted the Mode of action definitions (metabolic, pharmacologic and immunologic).

Update on CHMP opinion under Art. 57 (1)P of Regulation (EC) No 726/2004

Update on EC proposed Medical diagnosis definition

Call for expression of interest for CHMP and CAT Members to participate at the drafting group (att. ITFSecretariat@ema.europa.eu) by 28 March 2014.

It was suggested to appoint a new CHMP Coordinator (as lead) and the previous CHMP Coordinators involved in Art. 57 Scientific opinions which triggered this need to develop a definition on Fluorescent ophthalmic strips (Triamcinolone Acetonide and 5-AFL-HAS). Confirmation from these Members will be sought and any additional CHMP members involved in recent approval of Diagnostic Medicinal products will be welcome.

15.5 Nanomedicines activities

No items

16 SCIENTIFIC ADVICE WORKING PARTY (SAWP)

Report from the SAWP meeting held on 3-5 March 2014. Table of conclusions: **For information**	
Scientific advice letters:	*Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.*
PDCO proposal for a Strategic PIP for the development of medicinal products in Gaucher's Disease'.	

17 SATELLITE GROUPS

17.1 Coordination Group for Mutual Recognition and Decentralised Procedures

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 17-19 March 2014: **For information**	The CHMP noted the report.

18 OTHER COMMITTEES

18.1 Committee for Orphan Medicinal Products (COMP)

Press release of the COMP meeting held on11-12 March 2014: **For information**	To be sent in the Post-mail.

18.2 Committee for Herbal Medicinal Products (HMPC)

No items

18.3 Paediatric Committee (PDCO)

PIPs reaching D30 at March 2014 PDCO: **For information**	To be sent in the Post-mail.
Report from the PDCO meeting held on held on 19-21 March 2014: **For information**	The CHMP noted the report.

18.4 Committee for Advanced Therapies (CAT)

Table of Decisions of CAT meeting held on 13-14 March 2014: **For information**	The CHMP noted the Table of Decision.

19 INVENTED NAME ISSUES

Table of Decisions of the NRG meeting held on March 2014: **For adoption**	The CHMP noted the Table of Decision.

20 ANY OTHER BUSINESS

Election of BWP Vice Chair	The election was postponed to the plenary meeting in April 2014.
Infectious Diseases Working Party IDWP Work Programme for 2014: **For adoption**	The CHMP adopted the IDWP Work Programme for 2014. Nominations should be sent to IDWPSecretariat@ema.europa.eu by 18th April 2014.
Blood Products Working Party BPWP Work Programme for 2014: **For adoption** Request to the CHMP for Member States representation at BPWP	The CHMP adopted the BPWP Work Programme for 2014 and agreed that a call for nominations was not necessary as representation at BPWP remains per Member States.
Feedback from the PCWP and HCPWP joint meeting workshop held on 26 February on regulatory and methodological standards to improve benefit/risk evaluation of medicines: **For information**	The CHMP noted the feedback from the PCWP and HCPWP joint meeting workshop held on 26 February on regulatory and methodological standards to improve benefit/risk evaluation of medicines and welcomed the interest in such area.
Pilot phase proposal to involve patients in CHMP oral explanations: **For information**	The CHMP noted the pilot phase proposal to start involving patients in some Oral Explanation held at CHMP in the future. The Committee noted that this proposal could possibly be trialled from September 2014 onwards providing that relevant oral explanations were identified and that the additional work required to implement this pilot phase has been completed. This topic will be further discussed at the informal CHMP meeting at

	the end of May.
Move to Churchill Place	The Committee was informed about the industry facilities in the new building. They were shown drawings of the industry lounge and learnt about the facilities, including 4 meeting rooms and visitor WiFi access. Guidelines for industry representatives will be prepared by EMA.
Q&A on practical implementation of Article 20 Pharmacovigilance Procedure (EMA/796802/2013): **For discussion**	The Committee noted the latest amendments made in the document following the preliminary ORGAM discussion on 10th March (i.e. implementation of comments received from CHMP Member). The Committee agreed to have more time to review/comment on the matter.
Updated template for Reader's Guidance document: Addition of field for PRAC's input in relevant procedure: **For adoption**	The CHMP adopted the updated template for Reader's Guidance document, which has been amended to include a field for PRAC's input in relevant procedure. This revised guidance should be used from April onwards.
Change of procedure for disclosure of invented names of Orphan medicinal products prior to the adoption of CHMP Opinion: **For information**	The CHMP noted that from March onwards the invented names of orphan products will no longer be disclosed due to alignment with the principles on publication of agendas and minutes of EMA Scientific Committees adopted by the Management Board in December 2013.
Procedure for coordinating GCP inspections as requested by CHMP: **For adoption**	Follow up from February 2014. The CHMP adopted the Procedure for coordinating GCP inspections.
Request from the HMPC to the SWP on conclusions of a toxicological assessment of estragole and alkenylbenzenes: **For information**	The CHMP noted the request from the HMPC to the SWP on conclusions of a toxicological assessment of estragole and alkenylbenzenes.
Request from the CMDh to the SWP on safety margin following systematic absorption: **For information**	The CHMP noted the CMDh request to the SWP on safety margin following systematic absorption.
Request from the CMDh to the SWP on qualification of flecainide as narrow therapeutic index drug: **For information**	The CHMP noted the CMDh request to the SWP on qualification of flecainide as narrow therapeutic index drug.
Process for regulatory advice on Combination packaging of Medicinal Products Request for setting up a drafting group to elaborate on "scientific criteria" to determine the "exceptional circumstance" to allow combination pack: **For adoption**	Follow up from March ORGAM meeting The CHMP adopted a process for regulatory advice on Combination packaging of Medicinal Products.
Update on the future EMA product team support	

for evaluation activities: **For information**	The Committee noted the update on the future EMA product team support for evaluation activities which will be introduced from 1st April for some procedures. The concept of an EMA Product Leader and Business Manager are being introduced. The Committee understood the need for changes but nevertheless expressed some concerns regarding the practicalities of implementation and pointed out the risk of an increase coordination that will be required.
Drafting group on the asthma guideline Call for expression of interest for CHMP Members to participate at the drafting group to finalise the revision of the Asthma guideline	The Committee noted the decision to cease activities of the Respiratory Drafting Group for the time being and set up a specific drafting group to finalise the revision of the Asthma guideline.
International Standards on Identification of Medicinal Product (ISO IDMP) – current status and next steps	Session aimed to provide an update on the international activities and the plan for the implementation of the ISO Identification of Medicinal Products Standards EMA will draft a list of expertise required for the European Task Force.
Update of geriatric section of assessment reports and guidance following initial experience CHMP D210 assessment report template and guidance, Day 120 LoQ, Day 80 clinical assessment report and Day 80 assessment report overview templates and guidances.	The Committee noted the update of the geriatric section of assessment reports and guidance provided following initial experience. Documents updated are CHMP D210 assessment report template and guidance, Day 120 LoQ, Day 80 clinical assessment report and Day 80 assessment report overview templates and guidances.

21 **List of participants:** *including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 17-20 March 2014 meeting.*

CHMP Chair	***Country***	***Outcome restriction following evaluation of e-DoI for the meeting***	***Topics on the current Committee Agenda for which restriction applies*** ***Product/ substance***
Tomas Salmonson	Sweden	Full involvement	

CHMP Member	***Country***	***Outcome restriction following evaluation of e-DoI for the meeting***	***Topics on the current Committee Agenda for which restriction applies*** ***Product/ substance***
Andrea Laslop	Austria	Full involvement	
Daniel Brasseur	Belgium	Full involvement	
Mila Vlaskovska	Bulgaria	Full involvement	
Ivana Mikačić	Croatia	Full involvement	
Panayiotis Triantafyllis	Cyprus	Full involvement	
Jens Heisterberg	Denmark	No participation in final deliberations and voting on:	Seroquel IR&XR (EMA/H/A-30/1362) (quetiapine)
Alar Irs	Estonia	Full involvement	
Outi Mäki-Ikola	Finland	No participation in final deliberations and voting on:	(EMEA/H/C/003729) (secukinumab)
			Stelara (EMEA/H/C/000958/II/0036) (ustekinumab)
			Humira (EMEA/H/C/000481/II/0127), (adalimumab)
Pierre Demolis	France	Full involvement	
Harald Enzmann	Germany	Full involvement	

CHMP Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance
Dimitrios Kouvelas	Greece	Full involvement	
Agnes Gyurasics	Hungary	Full involvement	
Kolbeinn Gudmundsson	Iceland	Full involvement	
David Lyons	Ireland	Full involvement	
Romaldas Mačiulaitis	Lithuania	Full involvement	
John Joseph Borg	Malta	Only connecting via TC on Envarsus - Tacrolimus veloxis	
Pieter de Graeff	Netherlands	Full involvement	
Karsten Bruins Slot	Norway	Full involvement	
Piotr Fiedor	Poland	Full involvement	
Bruno Sepodes	Portugal	Full involvement	
Nela Vilceanu	Romania	Full involvement	
Concepcion Prieto Yerro	Spain	Full involvement	
Kristina Dunder	Sweden	Full involvement	
Greg Markey	United Kingdom	Full involvement	
Sol Ruiz	Co-opted	Full involvement	
Robert James Hemmings	Co-opted	Full involvement	
Jan Mueller-Berghaus	Co-opted	Full involvement	
Jean-Louis Robert	Co-opted	Full involvement	
Hubert Leufkens	Co-opted	Full involvement	

CHMP Alternate	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product/* *substance*
Milena Stain	Austria	Full involvement	
Bart Van der Schueren	Belgium	Full involvement	
Ana Dugonjić	Croatia	Full involvement	
Radka Montoniová	Czech Republic	Full involvement	
Jens Ersbøll	Denmark	Full involvement	
Janne Komi	Finland	No participation in final deliberations and voting on:	Estradiol (topical use) (EMEA/H/A-31/1336)
			(EMEA/H/C/002780), (ospemifene)
Joseph Emmerich	France	No participation in final deliberations and voting on:	Eliquis (EMEA/H/C/002148/II/0014/G) (apixaban)
			Seroquel IR&XR (EMA/H/A-30/1362) (quetiapine)
Martina Weise	Germany	Full involvement	
Reynir Arngrímsson	Iceland	Full involvement	
Patrick Salmon	Ireland	Full involvement	
Daniela Melchiorri	Italy	Full involvement	*Replacing CHMP member*
Natalja Karpova	Latvia	Full involvement	*Replacing CHMP member*
Johann Lodewijk Hillege	Netherlands	Full involvement	
Ingunn Hagen Westgaard	Norway	Full involvement	
Aldona Paluchowska	Poland	Full involvement	

CHMP Alternate	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product/* *substance*
Dinah Duarte	Portugal	Full involvement	
Jana Klimasová	Slovakia	Full involvement	*Replacing CHMP member*
Nevenka Tršinar	Slovenia	Full involvement	*Replacing CHMP member*
Arantxa Sancho-Lopez	Spain	Full involvement	
Bengt Ljungberg	Sweden	Full involvement	
Rafe Suvarna	United Kingdom	Full involvement	

European Commission	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product/* *substance*
	European Commission	Full involvement	

CHMP Expert	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product/* *substance*
* Experts were only evaluated against the product they have been invited to talk about.			
Valerie Lescrainier	Belgium	Full involvement	
Maria Kovacova	Czech Republic	Full involvement	
Trine Jensen	Denmark	Full involvement	
Kristiina Airola	Finland	Full involvement	
Veera Torkko	Finland	Full involvement	
Marine Moreau	France	Full involvement	
Marc Martin	France	Full involvement	
Muriel Uzzan	France	Full involvement	
Ljiljana Milosevic-Kapetanovic	France	Full involvement	
Isabelle Yoldjian	France	Full involvement	
Dahlia Saccal Diab	France	Full involvement	
Sabine Mayrhofer	Germany	Full involvement	
George Aislaitner	Greece	Full involvement	
Maaike van Dartel	Netherlands	Full involvement	
Filip Josephson	Sweden	Full involvement	

CHMP Expert	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product/* *substance*
Ana Alonso Gutierrez	Spain	Full involvement	
John Johnston	United Kingdom	Full involvement	
Anjana Aggarwal	United Kingdom	Full involvement	
Benoy Daniel	United Kingdom	Full involvement	
Mair Powell	United Kingdom	Full involvement	

CHMP Expert by phone	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product/* *substance*
* Experts were only evaluated against the product they have been invited to talk about.			
Jannik Helweg-Larsen	Denmark		
Sargi Caizergues Lama	France		
Michael Pfleiderer	Germany		
Beate Ziegeler	Germany		
Ralf Meyer	Germany		
Henrike Potthast	Germany		
Nils Lilienth	Germany		
Jutta Hessling	Germany		
Geraldine O'Dea	Ireland		
Marco Massari	Italy		
Chetcuti Michael	Malta		
Irene Bosselaers	Netherlands		
Ita Walsh	Netherlands		
Paula Boudewina van Hennik	Netherlands		
Marjon Pasmooij	Netherlands		
Jan Schellens	Netherlands		
Bertil Jonsson	Sweden		
Sven-Erik Hillver	Sweden		
Anders Lindblom	Sweden		
Mikael Andersson	Sweden		

CHMP Expert by phone	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product/* *substance*
Geoffrey Lay	United Kingdom		
Catherine Tregunno	United Kingdom		
Elizabeth Baker	United Kingdom		
Keith Chidwick	United Kingdom		

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 1)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 2 and 3) or referral procedures (section 12) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

New applications *(section 2)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 2.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 2.2 (**Day 180 List of outstanding issues**) and 2.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 2.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 2.5, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 3)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 4)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 3. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 5)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 6)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 7)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 8)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 9)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 10)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 11)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 12)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 13)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 14)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 15)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 16)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 17)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 18)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.